1008361-65-6 Usage
General Description
5-Bromo-6-methoxybenzoimidazole is a specialty chemical compound that falls within the class of organic compounds known as benzimidazoles. As its name suggests, it contains a benzene and imidazole ring fused together, and has bromine and methoxy group substitutions at the 5th and the 6th positions respectively. It is a synthesizable compound often purposed for research and experimentation in the field of synthetic chemistry. The specific properties such as color, density, and solubility of the compound can be dependent on its purity and other conditions. It is a solid substance at room temperature and not naturally occurring, hence it is manufactured artificially. It is rarely used in industry and primarily serves the scientific community. Overall it should be handled with care in a controlled environment as its hazard and toxicity levels are currently not very well characterized.
Check Digit Verification of cas no
The CAS Registry Mumber 1008361-65-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,8,3,6 and 1 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1008361-65:
(9*1)+(8*0)+(7*0)+(6*8)+(5*3)+(4*6)+(3*1)+(2*6)+(1*5)=116
116 % 10 = 6
So 1008361-65-6 is a valid CAS Registry Number.
1008361-65-6Relevant articles and documents
Heterocyclic compound used as MNK inhibitor
-
Paragraph 0253; 0255, (2019/01/08)
The invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method thereof, and application thereof used as a mitogen activated protein kinase interacting kinase 1 and 2-MNK1/MNK2 inhibitor. The inhibitor is the heterocyclic compound as shown in the formula (I), or its pharmaceutically acceptable salt, prodrug, solvent compound, polycrystal, isomer, stable isotope derivative or a pharmaceutical composition containing the heterocyclic compound. The compound of the invention can be used for treating or preventing MNK-mediatedrelated diseases, such as cancers.
HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES
-
, (2016/08/03)
Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
